Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Shares, par value (euro)0.12 per share
-
Shares outstanding
-
22,421,536
-
Total 13F shares
-
7,605,083
-
Share change
-
+7,582,080
-
Total reported value
-
$355,419,000
-
Put/Call ratio
-
95%
-
Price per share
-
$46.55
-
Number of holders
-
42
-
Value change
-
+$354,349,010
-
Number of buys
-
40
Institutional Holders of CureVac N.V. - Common Shares, par value (euro)0.12 per share (CVAC) as of Q3 2020
As of 30 Sep 2020,
CureVac N.V. - Common Shares, par value (euro)0.12 per share (CVAC) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,605,083 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, PRICE T ROWE ASSOCIATES INC /MD/, DekaBank Deutsche Girozentrale, Samsara BioCapital, LLC, MILLENNIUM MANAGEMENT LLC, Novo Holdings A/S, HILLHOUSE CAPITAL ADVISORS, LTD., Vivo Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
42
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.